The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
about
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia CellsHistone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemiaPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?New and emerging HDAC inhibitors for cancer treatmentConcurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionDeath on the slopes. Symposium on Cell Death Pathways.Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataBET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphomaThe histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cellsAutophagy: A potential target for thyroid cancer therapy (Review)The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsEffects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication.Autophagic and apoptotic effects of HDAC inhibitors on cancer cellsAugmenting antitumor immune responses with epigenetic modifying agents.Histone deacetylase inhibitors: emerging mechanisms of resistance.Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cellsDevelopment of a castrate resistant transplant tumor model of prostate cancerHistone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways.Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death.Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenibFunctional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling.Unfolded protein response to autophagy as a promising druggable target for anticancer therapy.Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.Therapeutic targeting of autophagy in disease: biology and pharmacology.Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphomap53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.Therapeutic targets in cancer cell metabolism and autophagy.Autophagy as a target for cancer therapy: new developmentsB-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.Histone deacetylase inhibitors and cell death.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Histone Deacetylase Inhibitors as Anticancer Drugs.
P2860
Q21328686-EADFE600-55EA-4F20-84E4-80A874C35940Q24633394-6D56ECB0-6FCD-46EF-829A-6C35B1EA715FQ26771601-A5210FEB-2188-47FB-90EE-A34D3AA302A1Q27022413-3E77ECDD-2142-410E-BBFA-BA3592CDFDA4Q28743074-EA2FE8FB-B6D4-4C56-B828-3941B585BFCBQ30489517-68914D4C-81A7-4FD0-9DB3-0CA0EA21A229Q30936712-24380629-150C-416E-B461-2F7A800B7DAEQ33853887-4A811373-C948-43D4-BD6C-2D74092148F7Q33928765-EEA2F212-31C6-44BA-B888-E6B5790BADF3Q33933013-EC7EB17E-E977-43E3-B49E-B25D21F4E058Q33934350-AE771EC5-9861-4C26-B332-542D1E2D8FDEQ34399444-7C564600-A03C-45FB-B1E2-997FBA9CA797Q34652570-756E8750-502B-419F-A3BF-CED1F9E032AEQ34658892-11280247-C2B4-4809-9CE7-D960C8AF0D49Q34960201-4E75CF04-5065-407E-AC1F-A15B6BE2FBC4Q35001459-3A478F95-A2CF-40B3-A00B-C43394A2A12BQ35048054-C2974E45-F9CF-4C5A-B9C9-DC104B9C3C70Q35592607-900E9D62-DAAE-4E76-BE8A-366B48590F60Q35677279-4FD8E10D-FEA6-47F5-82D2-B879783D041EQ35819316-47E3676A-35EB-4B7F-9C2C-72F6C17646FBQ35852901-2EB988FC-F9B7-44DB-8C7D-CEFD2A5F6D70Q35922012-6DF368BF-5E20-4D66-895E-4F8E50BDB784Q35968727-BCBF2136-ECD4-4821-83F4-0D18A6275087Q36301520-EB83347C-E794-46B3-AD2C-DCAED3507EC6Q36356381-13375D37-E94F-4441-A7EC-11A3972A20D4Q36403652-C531ABDA-7687-40A4-8A72-377DD5AE0C28Q37211962-FE1B3E2B-C59A-4E48-A94B-0372AA8139F8Q37236107-FC34FC7E-520D-435A-BE7B-EE6540B66024Q37439209-9E33EA1A-8D9A-4221-8D3D-16BB5C61F01CQ37558978-9E9F73A3-CA5B-4B3B-ABFA-5571F4873598Q37821337-76D33DA6-9DA4-42D7-B07E-619F48A39793Q37993586-9787DD88-EA93-4ACE-84B2-EAB5241AC6A1Q38025264-3694A046-6EB8-4077-BF8F-78EEB3D31EECQ38054710-D0DD8464-F939-45B0-A50B-29EAB6CE3110Q38124120-EBAE88F3-85BB-4316-8255-8FCC639E782AQ38217666-5BBC76E1-86BD-423F-8C9A-DA665726D400Q38240733-095C9634-6F0B-4C63-951E-A4F8FB939901Q38388674-1E0355B8-D4FC-48E0-B57A-94B3D0D25D73Q38572855-129A70A5-8FFD-428F-BD41-705C14622314Q38696932-6A01FC28-302E-48E9-95C8-00714A823E5C
P2860
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
The histone deacetylase inhibi ...... death or therapeutic efficacy.
@ast
The histone deacetylase inhibi ...... death or therapeutic efficacy.
@en
type
label
The histone deacetylase inhibi ...... death or therapeutic efficacy.
@ast
The histone deacetylase inhibi ...... death or therapeutic efficacy.
@en
prefLabel
The histone deacetylase inhibi ...... death or therapeutic efficacy.
@ast
The histone deacetylase inhibi ...... death or therapeutic efficacy.
@en
P2093
P2860
P1433
P1476
The histone deacetylase inhibi ...... death or therapeutic efficacy.
@en
P2093
Andrea Newbold
Clare L Scott
Jessica E Bolden
Leigh Ellis
Leonie A Cluse
Michael Bots
Peter Atadja
Ralph K Lindemann
Scott W Lowe
P2860
P304
P356
10.1182/BLOOD-2008-10-182758
P407
P577
2009-04-21T00:00:00Z